论文部分内容阅读
Studies have shown that Arnexin A2 (ANXA2) is related with tumor proliferation, apoptosis, and differentiation, invasion, migration, and drug resistance.The purpose of this study was to investigate the role and its mechanisms of ANXA2 in multi-drug-resistance (MDR) in gastric cancer.ANXA2 expression in both gastric cancer tissues and cell lines were detected by quantitative real-time PCR (RT-qPCR) and Western blotting.The cell proliferation was measured by SRB assay.The pool of siRNA against ANXA2 were designed and synthesized and then transfected into resistant gastric cancer SGC7901/DDP cells.ANXA2 expression was detected by RT-qPCR and Western blotting.Drag sensitivities of SGC7901/DDP cells to P-gp-related drug (doxorubicin) and P-gp-non-related drugs (5-FU and cisplatin) were measured by SRB assay.Results showed that expression of MDR-related genes and phosphorylation of AKT and MAPKs were also detected by RT-qPCR and Western blotting.ANXA2 expression was significantly higher in gastric specimens than that in normal tissues, and negatively correlated with the differentiation level of gastric cancer.In addition, ANXA2 expression level was higher in SGC7901/DDP cells than that in parent SGC7901 cells.After knock-down ANXA2 expression using ANXA2 small interfering RNA, the drug sensitivity of SGC7901/DDP cells to doxorubicin, 5-FU and DDP increased.Delivery of ANXA2 siRNA significantly downregulated the expression of P-gp, MRP1 and Bcl-2, while markedly upregulated Bax in SGC7901/DDP cells.However, several other MDR factors such as GST-π, TOPO-Ⅱ and TOPO-Ⅱ had no obvious changes.Additionally, phosphorylation of P38MAPK and AKT, but not ERK1/2 or JNKs was specifically decreased in SGC7901/DDP cells after ANXA2 siRNA delivery.Importantly, P38MAPK and AKT inhibitor increased the drug sensitivity of SGC701/DDP cells in a similar way as ANXA2 siRNAs does.ANXA2 is involved in gastric cancer MDR through regulating p38-MAPK and AKT pathways as well as certain MDR factors.